和黃醫藥於中國啟動惡性血液腫瘤抑制劑產品一期臨床試驗
和黃醫藥公布,於中國啟動抑制劑產品「HMPL-306」的一期臨床試驗,首名患者已於7月24日接受給藥治療。
該產品為靶向異檸檬酸脫氫(酉每)(IDH)1和2突變的新型雙重小分子抑制劑,是和黃醫藥自主研發的第9個腫瘤創新藥物,用於治療惡性血液腫瘤患者。是次試驗旨在評估HMPL-306在伴有IDH1和/或IDH2突變的復發性或難治性惡性血液腫瘤患者中的安全性、藥代動力學、藥效學和療效,有望為具有IDH突變的癌症患者提供治療效益,並可能解決因亞型轉化導致的IDH抑制獲得性耐藥問題。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.